NetworkNewsBreaks – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces Positive FDA Pre-IND Guidance for Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biotechnology company specializing in the development of novel treatments for brain tumors, received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use Berubicin, a lyophilized drug product, in Phase II clinical trials. The FDA indicated, in response to CNS Pharmaceuticals’ previously-submitted Pre-IND request, that the proposal to use a lyophilized drug product in the Phase II clinical trial appears reasonable. "We were encouraged by the initial feedback provided by the FDA as we believe the availability of our existing supply of Berubicin for a…







